中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 4
Apr.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(4): 712-719

Therapeutic effect of Xiayuxue decoction on a mouse model of nonalcoholic fatty liver disease induced by high-fat diet and its mechanism

DOI: 10.12449/JCH240412
  • a.

    Laboratory of Experimental Center, Putuo Hospital，Shanghai University of Traditional Chinese Medicine，Shanghai 200062，China

  • b.

    Department of Infectious Diseases，Putuo Hospital，Shanghai University of Traditional Chinese Medicine，Shanghai 200062，China

Research funding:

National Natural Science Foundation of China (82004106);

National Natural Science Foundation of China (81873136);

Putuo Hospital Talent Project (2022-RCJC-04);

Putuo Hospital Talent Project (2022-RCJC-02);

Shanghai Natural Science Foundation of China (20ZR1450300);

Putuo District of Shanghai Innovation Project (ptkwws202223);

Putuo District of Shanghai Innovation Project (ptkwws202112);

Scientific Research Fund of Shanghai Sixth People’s Hospital Medical Group (21-ly-02);

Xinglin Scholar of Chengdu University of Traditional Chinese Medicine (YYZX2020117);

Shanghai High Level Talent Leadership Plan for Traditional Chinese Medicine (［2021-2023］-0403)

More Information
  • Corresponding author: WU Liu， wlcrystal@126.com （ORCID： 0000-0003-0720-819X）
  • Received Date: 2023-06-05
  • Accepted Date: 2023-08-03
  • Published Date: 2024-04-25
    Abstract
  •   Objective  To investigate the mechanism of action of Xiayuxue decoction in inhibiting nonalcoholic fatty liver disease （NAFLD） induced by high-fat diet in mice by regulating nucleotide binding oligomerization domain like receptor containing pyrin domain protein 6 （NLRP6）.  Methods  A total of 15 male C57BL/6 mice were randomly divided into low-fat diet （LFD） group， high-fat diet （HFD） group， and Xiayuxue decoction-HFD group （XYXD group）， with 5 mice in each group. Liver function parameters （alanine aminotransferase ［ALT］ and aspartate aminotransferase ［AST］） and blood lipid metabolic indicators （triglycerides ［TG］ and total cholesterol ［TC］） were measured； HE staining and oil red O staining were performed for liver tissue to observe histomorpholoty and lipid droplet deposition； quantitative real-time PCR was used to measure the expression levels of inflammatory factors （tumor necrosis factor-α ［TNF-α］， interleukin-1β ［IL-1β］， interleukin-18 ［IL-18］， and NLRP6） in liver tissue； Western blot was used to measure the protein expression levels of NLRP6， nuclear factor-kappa B （NF-κB）， and NF-κB p65； immunohistochemistry was used to measure the expression of NLRP6 and CD68. Mouse Raw264.7 cells were treated with palmitic acid （PA）， lipopolysaccharide， and serum containing Xiayuxue decoction to observe inflammation. A one-way analysis of variance was used for comparison of continuous data between multiple groups， and the least significant difference t-test was used for further comparison between two groups.  Results  Compared with the LFD group， the HFD group had significant increases in the serum levels of ALT， AST， TC， and TG （all P<0.05）. Liver histopathological examination showed that the HFD group had marked hepatic steatosis and a signficant increase in NAS score （P<0.05）， and quantitative real-time PCR showed significant increases in the inflammatory factors such as IL1β and IL-18 and a significant reduction in the expression of NLRP6 （all P<0.05）. Immunohistochemistry showed that the expression of NLRP6 showed a similar trend as that of the macrophage marker CD68. Western blot showed that after the downregulation of NLRP6 expression， there was a significant increase in phosphorylated NF-κB p65 （P<0.05）. Compared with the HFD group， Xiayuxue decoction effectively improved liver inflammation， upregulated the expression of NLRP6， and downregulated phosphorylated NF-κB p65 in HFD mice （all P<0.05）. After Raw264.7 cells were treated with PA， NLRP6 was downregulated to promote the progression of inflammation （P<0.05）， and treatment with Xiayuxue decoction could upregulate NLRP6 and inhibit inflammation NF-κB （P<0.05）.  Conclusion  Xiayuxue decoction can effectively improve hepatic steatosis and liver inflammation in a mouse model of NAFLD， possibly by regulating NLRP6/NF-κB to alleviate macrophage activation.

     

    • FullText(HTML)
  • loading
    • References(14)
  • [1]
    NATARAJAN Y, KRAMER JR, YU X, et al. Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes[J]. Hepatology, 2020, 72( 4): 1242- 1252. DOI: 10.1002/hep.31157.
    [2]
    ZHOU F, ZHOU JH, WANG WX, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology, 2019, 70( 4): 1119- 1133. DOI: 10.1002/hep.30702.
    [3]
    WU L, ZHANG J, MA WT, et al. Xiayuxue decoction inhibits methionine-choline-deficient-induced nonalcoholic steatohepatitis in mice[J/OL]. Chin J Liver Dis Electron Version, 2018, 10( 3): 48- 55. DOI: 10.3969/j.issn.1674-7380.2018.03.009.

    吴柳, 张洁, 马文婷, 等. 下瘀血汤对胆碱蛋氨酸缺乏诱导的小鼠非酒精性脂肪性肝炎的抑制作用[J/OL]. 中国肝脏病杂志(电子版), 2018, 10( 3): 48- 55. DOI: 10.3969/j.issn.1674-7380.2018.03.009.
    [4]
    KLEINER DE, BRUNT EM, VAN NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41( 6): 1313- 1321. DOI: 10.1002/hep.20701.
    [5]
    SHI XJ, TAN X, ZHANG XS, et al. Discussion on medication rule of non-alcoholic fatty liver disease based on national patent of traditional Chinese medicine compound[J]. Chin Med Herald, 2022, 19( 20): 148- 151, 156.

    施晓军, 谭祥, 章晓思, 等. 基于国家中药复方专利探讨非酒精性脂肪性肝病的用药规律[J]. 中国医药导报, 2022, 19( 20): 148- 151, 156.
    [6]
    Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Expert consensus on TCM diagnosis and treatment of nonalcoholic fatty liver disease(2017)[J]. J Clin Hepatol, 2017, 33( 12): 2270- 2274. DOI: 10.3969/j.issn.1001-5256.2017.12.002.

    中华中医药学会脾胃病分会. 非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J]. 临床肝胆病杂志, 2017, 33( 12): 2270- 2274. DOI: 10.3969/j.issn.1001-5256.2017.12.002.
    [7]
    ALSHAWSH MA, ALSALAHI A, ALSHEHADE SA, et al. A comparison of the gene expression profiles of non-alcoholic fatty liver disease between animal models of a high-fat diet and methionine-choline-deficient diet[J]. Molecules, 2022, 27( 3): 858. DOI: 10.3390/molecules27030858.
    [8]
    BIJNEN M, JOSEFS T, CUIJPERS I, et al. Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice[J]. Gut, 2018, 67( 7): 1317- 1327. DOI: 10.1136/gutjnl-2016-313654.
    [9]
    KAZANKOV K, JØRGENSEN SMD, THOMSEN KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 3): 145- 159. DOI: 10.1038/s41575-018-0082-x.
    [10]
    WANG XJ, DE CARVALHO RIBEIRO M, IRACHETA-VELLVE A, et al. Macrophage-specific hypoxia-inducible factor-1α contributes to impaired autophagic flux in nonalcoholic steatohepatitis[J]. Hepatology, 2019, 69( 2): 545- 563. DOI: 10.1002/hep.30215.
    [11]
    HENAO-MEJIA J, ELINAV E, JIN CC, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J]. Nature, 2012, 482( 7384): 179- 185. DOI: 10.1038/nature10809.
    [12]
    CORRIDONI D, SIMMONS A. Innate immune receptors for cross-presentation: The expanding role of NLRs[J]. Mol Immunol, 2019, 113: 6- 10. DOI: 10.1016/j.molimm.2017.11.028.
    [13]
    MAINZ RE, ALBERS S, HAQUE M, et al. NLRP6 inflammasome modulates disease progression in a chronic-plus-binge mouse model of alcoholic liver disease[J]. Cells, 2022, 11( 2): 182. DOI: 10.3390/cells11020182.
    [14]
    LI MF, CHEN YT, SHI JR, et al. NLRP6 deficiency aggravates liver injury after allogeneic hematopoietic stem cell transplantation[J]. Int Immunopharmacol, 2019, 74: 105740. DOI: 10.1016/j.intimp.2019.105740.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(8)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (367) PDF downloads(45) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return